Reforgene named a Guangzhou Future Unicorn for the third consecutive year

Recently, the Guangzhou Unicorn list was grandly released at the 2024 China Overseas Talent Exchange Conference. Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene"), focused on innovative R&D of gene editing medicines, was successfully selected as a "Future Unicorn" innovative enterprise. It is worth noting that Reforgene has received this honor for three consecutive years. The continued recognition is not only affirmation by the government and industry of Reforgene's innovation capability and development potential, but also highlights Guangzhou's outstanding achievements in cultivating technology innovation enterprises.

The 2024 Guangzhou Unicorn innovative enterprises list is guided by the Guangzhou Municipal Science and Technology Bureau, hosted by the Guangzhou Science and Technology Innovation Enterprises Association, jointly released by the Guangzhou Industrial Development Research Institute and the Guangzhou Science and Technology Innovation Enterprises Association, and co-organized by China Construction Bank Guangzhou Branch. It aims to deeply implement the innovation-driven development strategy, identify a group of Guangzhou "unicorn" and "potential unicorn" enterprises with strong innovation, fast growth and great development potential, cultivate growth-oriented innovative enterprises, and give play to the leading and driving role of the new economy.

This honor encourages us to continue deepening innovative R&D of gene editing medicines, accelerate the transformation of innovative achievements into clinical applications, and bring curative treatment options to patients worldwide. We will cherish this honor, keep forging ahead, promote the progress of gene editing technology, and contribute Chinese wisdom and strength to the global health cause.